Objective To analyze the efficacy, safety and cost-effectiveness of imported sequential domestic rituximab in the treatment of non-Hodgkin's lymphoma. Methods The clinical data of 47 patients with non-Hodgkin's lymphoma treated with rituximab combined with chemotherapy in Fuyang People's Hospital from September 2018 to January 2021 were retrospectively analysed; based on the different rituximab sources, the patients were divided into the imported group (treated with pure imported rituximab) with 35 cases and the sequential domestic group (treated with imported sequential domestic rituximab) with 12 cases. After three courses of treatment, the short-term anti-tumor efficacy, adverse reactions during treatment, and patient cost-effectiveness were compared between the two groups.After 12 months of follow-up, the cumulative survival rates of the two groups were compared.Results After three courses of treatment, there was no statistically significant difference in the remission rate between the two groups of patients (P>0.05). In terms of the complications (fatigue, nausea and vomiting, hair loss, white blood cell decline rate) between the two groups of patients during treatment, there was no statistically significant difference (P>0.05). By the end of the follow-up, the cumulative survival rate of the imported group and the imported sequential domestic group was 85.70% and 83.30 respectively. there was no statistically significant difference in the survival curves between the two groups (P>0.05). The effect/cost ratio of the imported group and the sequential domestic group was 522.32 yuan and 274.92 yuan, respectively. The imported group was higher than the sequential domestic group, and each additional unit of effect would cost 8796.95 yuan more than the sequential domestic group.Conclusion Imported sequential domestic rituximab and pure imported rituximab have similar efficacy, safety and prognosis in the treatment of non-Hodgkin's lymphoma, but imported sequential domestic rituximab treatment cost-effectiveness is better than thesingle use imported rituximab. |